This BIOVIA customer uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility associated with the world of biotech. The company focuses on a range of illnesses including cancer, cardiovascular disease, diabetes, hepatitis B, HIV/ AIDS, rheumatoid arthritis and psychiatric disorders. Their R&D organization prioritizes pipeline velocity and sales growth while continuing to manage costs.

A multinational oil and gas company was utilizing BIOVIA Experiment software to support the day-to-day operations of scientists running experiments in the companies’ chemical operations division. These experiments were being conducted in three different laboratory locations worldwide, one of which had four servers on-premise that were being used to house the BIOVIA application and data center. The customer approached BIOVIA with a request for a cloud-based offering for BIOVIA Experiment, where it would be managed for the customer on a subscription basis. BIOVIA agreed to deploy a cloud-based offering of their Experiment application, and partnered with Astrix to provide the Managed Services.

The majority of electro-mechanical axis utilise extruded aluminium profile in a range of sizes with a single guide rail and bearing arrangement driven by an electric motor through a belt or ball screw arrangement. There are physical limitations to the forces such a system can accurately and reliably guide. This paper explores some alternative design arrangements to cope with higher load applications and identifies design considerations observed during the development of a Festo high load, twin rail system.

The trend in automation technology is towards smaller, multifunctional components. Compact one-way flow control valves type VFOF-LE-BAH are one of the latest developments in the field of pneumatics. By Peter Kronawitter

For over two decades, Astrix has been a trusted provider of world-class scientific staffing services across numerous industries such as life science, biotech, food and beverage, environmental, industrial and more.

LABORATORY NEWS

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM)